European Journal of Neurology
Author:
Keywords:
Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Neurosciences, Neurosciences & Neurology, clinical trial, Dravet syndrome, epileptic encephalopathy, orphan drug, refractory epilepsy, serotonin, severe myoclonic epilepsy in infancy, TREATMENT-RESISTANT EPILEPSY, VALVULAR HEART-DISEASE, CANNABIDIOL, POPULATION, DRUGS, Adolescent, Adult, Anticonvulsants, Child, Child, Preschool, Drug Therapy, Combination, Epilepsies, Myoclonic, Female, Fenfluramine, Humans, Infant, Male, Prospective Studies, Seizures, Treatment Outcome, Young Adult, 1103 Clinical Sciences, 1109 Neurosciences, Neurology & Neurosurgery, 3202 Clinical sciences, 3209 Neurosciences
Abstract:
Dravet syndrome (DS) is a severe, drug-resistant epilepsy. Fenfluramine has been reported to have a long-term clinically meaningful anticonvulsive effect in patients with DS.